Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSC vs FP for Asthma Control Guided by BHR
NCT01324362Phase 4Completed
- Sponsor
- GSK
- Start
- Jan 2003
- Primary completion
- Oct 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, double-blind trial of salmeterol in asthma (2 arms), sponsored by GSK. Primary endpoint: Average ICS treatment dose over the treatment period at 40 weeks. Started Jan 2003; status: completed.
02
Drugs
salmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01324362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01324362.